Revenue in the Second quarter amounted to 182.4 (142.4) MSEK, representing growth of 28.1 percent. The increase was driven by growth across all revenue categories. The significant growth in License revenue and Professional services stems from the successful development of the existing product as well as revenue from the SUSSA project. EBITDA in the second quarter amounted to 50.6 (25.7) MSEK resulting in an EBITDA margin of 27.7 (18.0) percent.

Comment from Peter Gille, CEO

Cambio’s priorities under current circumstances is to support our customers, to ensure our products fulfill their purpose without any interruptions and to protect the health and safety of our employees, Cambio has together with our existing customers taken actions to directly address Covid-19 effects with our software to make it possible to decrease administrative time, share information with municipalities and provide more intensive care units.

In the second quarter, Cambio continued to deliver solid profitable growth, underpinned by the quality of our products and our long-term commitment to society.

Please find the report here. For more information from Cambio, please visit

This information is information that Sanolium AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 2 pm CEST on 21 August 2020.